New drug combo aims to shrink liver tumors in colorectal cancer patients

NCT ID NCT06848842

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drug ivonescimab to standard chemotherapy can shrink liver tumors in people with colorectal cancer that has spread only to the liver and cannot be surgically removed. About 40 adults will receive the combination every 3 weeks for up to 8 cycles. The goal is to see if the tumors shrink enough to allow surgery or to control the disease. Researchers will also monitor side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL LIVER METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL LIVER METASTASES

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••